What "control" actually means in cold chain operations

We've been writing about the gap between compliance and control for a while now. If you've followed along, you already know the argument: a clean temperature log doesn't mean the product is fine. Documentation can satisfy an auditor without protecting a patient.

The most common response we've gotten to that argument is some version of “okay, so what does control actually look like?"

Here's a scenario that illustrates it. A shipment of insulin is sitting on a tarmac in Memphis in July. Tarmac surface temperatures can exceed 60°C [1]. The passive cooler's insulation is holding, but the internal temperature is trending upward. At this point, there are two versions of what happens next.

In version one, nobody knows. The data logger inside the box is recording at 15-minute intervals. It will capture whatever happens. When the shipment arrives at the distribution center, someone will pull the logger, download the data, and discover whether the product is still viable. If the temperature spiked between readings, they might not even catch it. This is monitoring.

In version two, a real-time alert fires when internal temperature crosses 5°C and is still climbing. A logistics coordinator sees the alert on a dashboard with the shipment's GPS location. She calls the ground handler. Fifteen minutes later, the package is in a temperature-controlled hold. The product never leaves range. That's control.

Same shipment. Same tarmac. Completely different outcome. The difference has nothing to do with packaging performance or regulatory compliance, but about whether anyone could see the problem and do something about it before the product was lost.

Monitoring and control aren't the same thing

The IQVIA Institute estimates that temperature excursions destroy roughly $35 billion in pharmaceutical products annually [2]. WHO data suggests nearly 25% of vaccines are compromised before reaching their final destination, with temperature failures as a leading cause [3]. A 2019 Biopharma Cold Chain Logistics Survey (the most recent comprehensive industry survey of its kind) found that 44.6% of respondents reported multiple excursions per year, and 16% said excursions were a monthly occurrence [4].

Nearly half the industry is dealing with this regularly and most of those shipments had monitoring in place when it happened. The monitoring did exactly what it was designed to do: record what happened. Recording what happened and preventing what happened are two completely different capabilities, and the industry has been treating them as interchangeable for too long.

What control requires

If monitoring is the autopsy, control is the immune system. It's the difference between knowing that a patient's temperature spiked overnight and having a system that adjusts the room temperature before the spike happens. Real control requires three things working together:

Active temperature management

The system is maintaining conditions. Passive packaging (gel packs, foam coolers, dry ice) works on a countdown. The moment you seal the box, the clock starts, and the insulation begins degrading. The approach assumes a best-case transit time, best-case ambient conditions, and no unexpected delays. When any of those assumptions break, so does the temperature envelope.

Active systems set a target temperature and maintain it mechanically. Think of the difference between packing a lunch in an insulated bag versus putting it in a refrigerator. One is a bet on how long the ice pack lasts. The other is climate control.

This isn't a new idea, but it matters more now because the margin for error has collapsed. Cell and gene therapies require cryogenic precision. Even conventional biologics are moving through longer, more fragmented supply chains with more handoff points than the packaging was designed for.

Real-time visibility

You can see conditions as they're happening. A data logger that you read when the shipment arrives is a historical record. Useful for compliance. Not useful for saving a $2.3 million insulin shipment that's been sitting at 12°C on a tarmac for the last half hour [1].

Someone, or some system, knows the temperature right now, continuously (not at 15-minute intervals). With location data attached so you know where the problem is.

Only about one-fifth of companies are aware of the environmental conditions their shipments travel through at any given time [5]. The rest are operating on assumption.

Intervention capability

The piece most organizations don't have and most vendors don't offer. Knowing that a shipment is at risk means nothing if you can't do anything about it.

Say an alert fires when temperature trends toward a threshold (not after it crosses), the alert reaches someone with the authority and ability to act, and that person has options. Reroute the shipment. Dispatch a replacement cooler. Pull it from the dock into a temperature-controlled hold. Adjust the unit's setpoint remotely.

This is where the ISPE's observation becomes relevant: a majority of cold chain losses stem from human error or lack of visibility rather than equipment failure [6]. Maybe you’ve successfully identified the issue, alerted the control tower, and sent someone to fix it. But do they know how and have a way to fix it? And how much time was lost in the process? 

Why the distinction keeps getting blurred

There's a reason the industry uses "control" loosely. Monitoring is easier to sell, easier to implement, and easier to document. You put a logger in the box, pull it out at the other end, and export a PDF. The auditor is satisfied.

For a long time, that was enough. When the products were shelf-stable enough to tolerate a few degrees of drift, when supply chains were shorter and more predictable, when regulators cared about endpoints and not the messy middle, monitoring was a reasonable proxy for control.

Now, however, the regulatory direction is tightening. The FDA's cGMP framework already requires documented temperature controls under 21 CFR 211, and the Drug Supply Chain Security Act (DSCSA) now mandates fully electronic, interoperable tracking to the package level across the entire prescription delivery supply chain, with civil penalties up to $500,000 per violation [7]. On the global side, WHO's Performance, Quality and Safety (PQS) program has expanded its device classifications to distinguish active temperature-controlled containers from passive ones, and the broader industry guidance is moving toward requiring data integration and intervention capability alongside temperature maintenance [8].

Three questions worth asking

If you're evaluating your cold chain operations, or evaluating vendors who claim to offer "control," three questions cut through the noise:

Can you set conditions, or are you hoping packaging holds?

If your approach relies on validating packaging performance under assumed conditions, you have a plan that works until conditions change…and conditions always change.

Do you know what's happening right now, or will you find out later?

Real-time doesn't mean "we'll have the data within a few hours." It means right now and with location. If your team can't tell you, at this moment, the temperature and location of every in-transit shipment, that's a visibility gap.

When something goes wrong, how do you intervene?

This is the hardest question and the most important one. Most organizations discover excursions after delivery. By then, the intervention options are limited to documentation, root cause analysis, and product disposition. All of which are important, none of which save the product.

The organizations that seem to be getting this right are treating these as one integrated system: set the conditions, watch what happens, and control the outcome when something drifts. Everything else, no matter what it says on the vendor's website, is some version of monitoring with better branding.

Ready to see what control looks like in practice?

Talk to our team about how Artyc's platform delivers active temperature management, real-time visibility, and intervention capability in a single system.

Sources:

[1] Biocair. "Temperature Excursions: Hidden Threats to Cold Chain Integrity." 2024. https://www.biocair.com/en/blog/temperature-excursions-cold-chain-integrity

[2] IQVIA Institute for Human Data Science, as cited by FreightWaves. "$35 billion saved: The digital shift in pharma logistics." 2024. https://www.freightwaves.com/news/35-billion-saved-the-digital-shift-in-pharma-logistics

[3] World Health Organization, as cited by FreightWaves. Ibid.

[4] Pelican BioThermal / ISTA. "2019 Biopharma Cold Chain Logistics Survey." 2019. https://cdn2.hubspot.net/hubfs/4107558/general%20content/PEL1046_SurveyReport_v4a.pdf

[5] PharmaSource. "Cold Chain Management: A Comprehensive Guide." 2024. https://pharmasource.global/content/guides/category-guide/cold-chain-management-a-comprehensive-guide/

[6] International Society for Pharmaceutical Engineering (ISPE), as cited by FreightWaves. "$35 billion saved: The digital shift in pharma logistics." 2024. https://www.freightwaves.com/news/35-billion-saved-the-digital-shift-in-pharma-logistics

[7] U.S. Food and Drug Administration. "Drug Supply Chain Security Act (DSCSA)." https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa; 21 CFR 211 (cGMP requirements for temperature controls).

[8] World Health Organization. "Performance, Quality and Safety (PQS) Devices Catalogue." https://apps.who.int/immunization_standards/vaccine_quality/pqs_catalogue/; Air Cargo Week. "Protecting vaccine shipments in 2026." 2025. https://aircargoweek.com/protecting-vaccine-shipments-in-2026-what-the-next-era-of-cold-chain-looks-like/